Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2021

In 2021, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 17.53% of shares outstanding on 15 Jan 2021 to 14.49% on 31 Dec 2021, a change of -3.04 percentage points. The year's high was 17.86% on 29 Jan 2021 and its low 10.26% on 30 Jul 2021, averaging 12.86% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.01 days on 29 Oct 2021. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2021

2021 in figures

Start of year
17.53% (15 Jan 2021)
End of year
14.49% (31 Dec 2021)
Change
-3.04 pp
High
17.86% (29 Jan 2021)
Low
10.26% (30 Jul 2021)
Average
12.86%
Highest days to cover
10.01 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

BIOCRYST PHARMACEUTICALS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202117.53%7.98
29 Jan 202117.86%6.42
12 Feb 202116.29%2.50
26 Feb 202116.32%4.79results (8-K)
15 Mar 202115.06%4.2310-K filed
31 Mar 202113.18%3.31
15 Apr 202114.10%8.51
30 Apr 202112.91%9.64
14 May 202112.45%4.67results (8-K), 10-Q filed
28 May 202111.26%5.87
15 Jun 202110.99%5.96
30 Jun 202110.78%4.92
15 Jul 202110.34%8.54
30 Jul 202110.26%7.34
13 Aug 202111.48%4.65results (8-K), 10-Q filed
31 Aug 202110.78%8.50
15 Sep 202110.61%8.55
30 Sep 202110.36%7.62
15 Oct 202110.60%7.75
29 Oct 202111.35%10.01
15 Nov 202112.53%5.52results (8-K), 10-Q filed
30 Nov 202113.44%8.47
15 Dec 202113.64%9.97
31 Dec 202114.49%9.78

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.